Mianus Clarity Fund

Our Mianus Clarity Fund focuses on driving innovation in ophthalmology globally with the goal of significantly improving people’s vision and quality of life.


As a global market, ophthalmology offers tremendous opportunities and less competition for venture capital investment. This is due to significant unmet medical needs, promising breakthrough technologies, strong barriers to entry, a clear path to exit for superior products, and strategic biopharma with nearly $1 trillion in acquisitive firepower.


Mianus Clarity Fund is a venture fund that focuses on investment in ophthalmology globally. We invest in promising companies that address unmet or underserved markets in ophthalmology, from early-stage Seed, Series A rounds in clinical trials, to late-stage rounds in commercialization.


Our fund has a unique advantage by leveraging our platform company, MERIT CRO, Inc. They are proud to be the market leader with a premier brand and unparalleled expertise in global ophthalmology clinical trials. MERIT provides access to high-quality deal flow, as well as scientific, clinical, and commercial expertise to support early to late-stage investments in the global ophthalmology market. We believe our unique advantage allows the fund to make better investments with exceptional returns.

Investment TEAM

The team at Mianus Clarity Fund consists of seasoned venture capitalists, entrepreneurs, investment bankers, and sophisticated investors. The team has vast domain knowledge and an extensive network in ophthalmology and other therapeutic areas, as well as an expanding network of high-profile partners and advisors in life sciences.


Leveraging MERIT and our portfolio company’s network, our fund has access to a distinguished group of scientists and ophthalmologists who are Key Opinion Leaders (KOL) supporting many ophthalmic clinical trials. Our scientific advisors help source and vet high quality deals, conduct due diligence, and provide assistance to our portfolio companies.

View our Ophthalmology Scientific Advisory Council members HERE

portrait of Steve Yang

Steve Yang, CFA, MBA

Founder and CEO

Mr. Yang has 25+ years of broad experience in capital markets, technology, life sciences, and management consulting. He is co-founder and CEO of Mianus Capital, and a Board member and CFO of MERIT CRO, Inc., a clinical endpoint solution provider. He previously held various management positions in banking and investment firms, including Nomura, Royal Bank of Scotland, and Black River Asset Management. Mr. Yang started his management career at McKinsey & Company in 2001. He earned an MBA with high distinction from the Ross School of Business at the University of Michigan. He also received a master's degree in computer science and a bachelor's degree in computer and electrical engineering from the University of Minnesota.

portrait of Arthur Klausner

Arthur Klausner, MBA

Managing Partner

A seasoned venture capitalist with 18+ years of investment experience, Mr. Klausner was a partner at Domain Associates and Pappas Ventures, two prominent venture funds in life sciences. He previously sat on the Board of Directors of the publicly traded company gastrointestinal drug company Santarus (SNTS) and currently serves on the Board of the publicly traded oncology company Monopar Therapeutics (MNPR). Among other start-up/operating roles, Mr. Klausner was the CEO and a board member of Jade Therapeutics, a developer of polymer-based products to treat poorly-served ophthalmic indications, which was acquired by EyeGate Pharmaceuticals. He is on the Life Sciences Investment Review Board for the New York University Innovation Venture Fund and a Chief Mentor for Endless Frontier Labs. Mr. Klausner began his venture capital career after earning an MBA at the Stanford University Graduate School of Business. He received his undergraduate degree in biology from Princeton University.

portrait of Yijun Huang

Yijun Huang, Ph.D.

Co-Founder and Venture Partner

Dr. Huang is a successful entrepreneur and corporate executive with 25+ years of business experiences in life sciences and solid expertise in ophthalmic clinical research and medical imaging. He is a Co-Founder and the CEO of MERIT CRO, Inc. Under his leadership, MERIT became the market leader in clinical endpoint assessment in global ophthalmology clinical trials. He also leads MERIT's expansion into a broad range of therapeutic areas beyond ophthalmology and in the Asia market. Prior to co-founding MERIT, Dr. Huang was VP of Engineering at Topcon Medical Systems and a Senior Scientist at the University of Wisconsin-Madison. He received his Ph.D. in Bioengineering from the University of Pennsylvania.

portrait of George Magrath

George Magrath, MD, MBA

Venture Partner

Dr. Magrath is currently the Chief Executive Officer and member of the Board of Directors of Ocuphire Pharma, Inc. (NASDAQ: OCUP). Prior to Ocuphire, Dr. Magrath was the Chief Executive Officer of Lexitas Pharmaceutical Services, Inc., where he led the company through significant growth, broadened its business lines, and increased revenue substantially. He successfully led Lexitas through the acquisition and integration process with QHP Capital, a top-tier private equity group, creating a premier ophthalmology contract research organization and generating significant value for investors. Prior to Lexitas, Dr. Magrath served as Medical Director to Hovione Pharmaceuticals, LLC, responsible for developing and advancing the company’s proprietary drugs in dermatology, ophthalmology and respiratory. He has served on many industry advisory boards and has authored numerous peer-reviewed publications.

portrait of Philip A Gioia

Philip A Gioia, MBA

Venture Partner

Mr. Gioia brings 30+ years of pharmaceutical industry experience as a transformational leader and ophthalmology specialist. He has an extensive track record of creating growth and delivering results in the brand and generic sectors. Mr. Gioia served as executive in residence at Warburg Pincus and is currently a senior advisor. He is a co-founder and board member of Vinci Pharmaceuticals, Inc., which is developing innovative drugs for retina diseases. He’s also a board member of Eye Therapies, LLC., and board advisor to Rebiotix, ORA Clinical, TearClear, Orasis, Ocugen, Mimetogen, and others. He was the president for North America Pharmaceuticals at Bausch & Lomb. Mr. Gioia earned his MBA from Sacred Heart University, Fairfield, CT, and an undergraduate degree from Montclair State University.

portrait of Karl Csaky

Karl Csaky, MD, Ph.D.

Dr. Csaky is the T. Boone Pickens director of the Clinical Center of Innovation for Age-Related Macular Degeneration, chief executive and chief medical officer of the Retina Foundation of the Southwest. His main area of interest is studying both clinical research and drug delivery development as it pertains to retinal diseases. Dr. Csaky is a member of the Macula Society, Retina Society, AAO, ARVO, American Ophthalmologic Society, and the American Society of Retinal Specialists. Dr. Csaky completed a retina fellowship at the Wilmer Eye Institute, Johns Hopkins University, and a post-doctoral fellowship at the National Cancer Institute. His internship was in medicine at Duke University, his ophthalmology residency at Washington University, and he was a Fulbright Scholar at the Essen Eye Clinic, Essen, Germany. Dr. Csaky received his combined MD/Ph.D. degree from the University of Louisville and has over 140 peer-reviewed publications and book chapters.

portrait of David S. Boyer

David S. Boyer, MD

Dr. Boyer is a world-renowned clinician, surgeon, and educator. He is one of the top 10 most influential retina specialists in the country, and a leading investigator for various national clinical trials on retinal diseases. Dr. Boyer serves as an advisor for multiple research, educational, and charitable institutions. He is senior partner at Retina Vitreous Associates Medical Group with offices in Los Angeles, Beverly Hills, North Hollywood, Torrance, Pasadena, and Tarzana, CA. Dr. Boyer is a clinical professor of ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, CA. He graduated from Chicago Medical School Rosalind Franklin University in 1972. He is affiliated with PIH Health Good Samaritan Hospital.

portrait of Deborah Ferrington

Deborah Ferrington, Ph.D.

Dr. Ferrington is the chief scientific officer at Doheny Eye Institute, a global leader in vision research and basic science. She serves as a permanent member of the National Institutes of Health Biology and Development of the Eye Study Section. Dr. Ferrington has 20+ years of experience in academic research, most recently as professor and Elaine and Robert Larson Endowed Vision Research Chair in the Department of Ophthalmology and Visual Neurosciences at the University of Minnesota, Twin Cities. She completed her undergraduate degree in biological science and scientific illustration, and a master of education program from the University of Pittsburgh. Dr. Ferrington went on to receive her Ph.D. in biochemistry from the University of Kansas, where she also completed a postdoctoral fellowship.

portrait of Antonio Capone Jr.

Antonio Capone, Jr., MD

Dr. Capone is a clinical associate professor of medical sciences at Oakland University in Michigan, and a partner at Associated Retinal Consultants in Royal Oak, Michigan. He is also a chief clinical officer at EyeCare Partners, a leading clinically-integrated network of ophthalmology and optometry providers. Dr. Capone is currently on the leadership board at the Retina Society, and completed an Emory Fellowship, one of the most prestigious in the U.S. He was president of the American Academy of Ophthalmology (AAO), and a member of the Alcon KOL Advisory Board. He received his medical degree from Brown University Medical School and completed an internship in internal medicine at Yale University.

portrait of Richard Lindstrom

Richard Lindstrom, MD

Dr. Lindstrom is founder and attending surgeon of Minnesota Eye Consultants and adjunct professor emeritus at the University of Minnesota Department of Ophthalmology. He is a board-certified ophthalmologist and an internationally recognized leader in corneal, cataract, refractive, and laser surgery. He has been at the forefront of ophthalmology’s evolutionary changes throughout his career, as a recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon. He holds over 30 patents in ophthalmology and has developed a number of solutions, intraocular lenses, and instruments that are used in clinical practices globally. He serves on the Board of Directors of AcuFocus, Inc, TLC Vision, Occulogix, eyeonics, Refractec, the Minnesota Medical Foundation, and Inner City Tennis. After graduating magna cum laude from the College of Liberal Arts at the University of Minnesota, Dr. Lindstrom completed his doctorate degree in medicine in 1972.

portrait of Julia A. Haller

Julia A. Haller M.D

Dr. Haller is one of the most respected and influential retina specialists in the world. She is a professor and chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University. She also holds the William Tasman, M.D., endowed chair at Wills Eye Hospital in Philadelphia, where she is ophthalmologist-in-chief. Dr. Haller is a member of the National Academy of Medicine, numerous international scientific advisory boards, and sits on the board of trustees of the Association of University Professors of Ophthalmology (AUPO), the College of Physicians of Philadelphia, and the Society of Heed Fellows. She earned her A.B. from Princeton University, magna cum laude. Dr. Haller received her medical training at Harvard Medical School, followed by an internship at Johns Hopkins, and a fellowship in ocular pathology at Manhattan Eye, Ear, and Throat Hospital. Her residency was at the Wilmer Eye Institute at Johns Hopkins Hospital, followed by a retina fellowship at Hopkins. Dr. Haller was appointed the first female Chief Resident at Wilmer in 1986.

portrait of Paul M. Karpecki

Paul M. Karpecki, OD, FAAO

Dr. Karpecki currently serves as director of cornea and external disease for the Kentucky Eye Institute in Lexington, KY. He is also the chief clinical editor for Review of Optometry and medical director for KEPLR Vision. Dr. Karpecki was appointed to the Delphi International Society at Wilmer Johns Hopkins, which included the top 25 dry eye experts in the world, and co-chair for the previous two Tear Film and Ocular Surface Society Symposia. He served on the DEWS II Diagnostic Methodology Committee. Dr. Karpecki is also an associate professor at the Kentucky College of Optometry at the University of Pikeville and serves on the board of the charitable organization Optometry Giving Sight. Dr. Karpecki received his doctor of optometry degree from Indiana University and completed a Durrie Fellowship in Medical Cornea/Refractive Surgery in Kansas City in affiliation with the Pennsylvania College of Optometry.

portrait of Jai G. Parekh

Jai G. Parekh, MD, MBA, FAAO

Dr. Parekh is a dual-trained internist and board-certified ophthalmic surgeon with experience and expertise in clinical and academic practice, pharmaceutical and medical device technology, medical affairs and R&D, and clinical development. He is the EVP/Chief Innovation Officer at EyeCheq. Previously, he was the chief medical officer and vice president of Eye Care at Allergan. Dr. Parekh is chief, cornea and external diseases, and medical director of the Research Institute at St. Joseph’s Health in NJ. He is a member of the Board of Trustees, the Foundation Board, and the Executive Committee of the healthcare system. Dr. Parekh has also co-founded three prestigious societies in eye care: American-European College of Ophthalmic Surgery (AECOS), CEDAR/ASPENS Society (CAS), and Vanguard Ophthalmology Society (VOS). He is clinical associate professor of ophthalmology in the Icahn School of Medicine at New York Eye and Ear Infirmary of Mount Sinai, NY. Dr. Parekh holds an MD from Boston University School of Medicine and an MBA from the Fuqua School of Business at Duke University.